Want to see GB:KMK full AI Analyst Report?
KMK Stock Chart & Stats
8.50 p
-0.29 p(-5.84%)
At close: 4:00 PM EST
8.50 p
-0.29 p(-5.84%)
Day’s Range― - ―
52-Week Range4.70 p - 13.00 p
Previous CloseN/A
Volume321.93K
Average Volume (3M)3.19M
Market Cap
£58.32M
Enterprise Value61.28M
Total Cash (Recent Filing)£1.25M
Total Debt (Recent Filing)£7.81M
Price to Earnings (P/E)4.6
Beta0.81
Next Earnings
Jul 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding655,299,900
10 Day Avg. Volume2,321,691
30 Day Avg. Volume3,192,291
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)0.63
Price to Sales (P/S)1.23
P/FCF Ratio2.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)£30.40M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained high top-line growth indicates expanding product adoption across security, nuclear and medical channels. Durable revenue momentum supports operating leverage, funds R&D and strengthens bargaining power with OEMs and government customers over the coming quarters.
Expanded Profitability & MarginsMaterial margin expansion and positive net margin point to proprietary technology and pricing power. Higher EBIT/EBITDA margins suggest improved cost structure and scalable operations, increasing resilience to cyclical demand and enabling reinvestment into product development.
Conservative Balance SheetVery low leverage and a strong equity base provide financial flexibility to fund development, absorb contract timing variability, and bid for larger government programs without refinancing strain, supporting multi‑quarter strategic execution.
Bears Say
Negative Free Cash Flow GrowthNegative FCF growth signals capex, working capital swings, or scaling costs are outpacing cash generation. Even with healthy operating cash conversion, persistent negative FCF can limit self‑funding for growth initiatives, slow deleveraging or constrain R&D and capital allocation choices.
Limited Forward VisibilityAbsence of formal guidance and call highlights reduces visibility into order timing, program awards and revenue cadence. For a business tied to government contracts and OEM design‑ins, limited disclosure increases forecasting uncertainty and complicates multi‑quarter operational planning.
Small Scale / HeadcountA relatively small workforce may constrain manufacturing scale, global sales coverage and program delivery for large defense or medical customers. Sustained growth could require outsized hiring or outsourcing, creating execution, quality and margin pressures over the medium term.
Kromek Group plc News
KMK FAQ
What was Kromek Group PLC’s price range in the past 12 months?
Kromek Group PLC lowest share price was 4.70 p and its highest was 13.00 p in the past 12 months.
What is Kromek Group PLC’s market cap?
Kromek Group PLC’s market cap is £58.32M.
When is Kromek Group PLC’s upcoming earnings report date?
Kromek Group PLC’s upcoming earnings report date is Jul 15, 2026 which is in 11 days.
How were Kromek Group PLC’s earnings last quarter?
Kromek Group PLC released its earnings results on Jan 20, 2026. The company reported 0.005 p earnings per share for the quarter, beating the consensus estimate of N/A by 0.005 p.
Is Kromek Group PLC overvalued?
According to Wall Street analysts Kromek Group PLC’s price is currently Overvalued.
Does Kromek Group PLC pay dividends?
Kromek Group PLC does not currently pay dividends.
What is Kromek Group PLC’s EPS estimate?
Kromek Group PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kromek Group PLC have?
Kromek Group PLC has 655,299,900 shares outstanding.
What happened to Kromek Group PLC’s price movement after its last earnings report?
Kromek Group PLC reported an EPS of 0.005 p in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -9.565%.
Which hedge fund is a major shareholder of Kromek Group PLC?
Currently, no hedge funds are holding shares in GB:KMK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kromek Group plc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.19%
12-Months-Change
Fundamentals
Return on Equity
22.93%
Trailing 12-Months
Asset Growth
-1.64%
Trailing 12-Months
Company Description
Kromek Group PLC
Kromek Group plc, a UK-based entity established in 2013 with headquarters in Sedgefield, specializes in the design, production, and global distribution of advanced radiation detection components and devices. These technologies provide high-resolution data on material composition and structure, serving critical applications across diverse markets such as medical imaging, the civil nuclear sector, CBRNe security, and safety screening. Its reach extends across the United Kingdom, North America, Asia, Europe, Australasia, and Africa. The company's innovative solutions are employed for various purposes, from identifying cancerous tissues and hazardous substances like explosives, to analyzing radioactive materials. Within the civil nuclear industry, Kromek offers sophisticated gamma and neutron detectors, high-specification, high-resolution devices, essential components, and specialized software designed to address complex nuclear detection challenges. These often utilize cadmium zinc telluride (CZT) or scintillator technologies for the detection of gamma rays, x-rays, and neutrons. For medical imaging, their portfolio includes CZT gamma detectors for SPECT, CZT bone mineral densitometry detectors, and cutting-edge photon-counting spectral CT systems. Kromek also provides CBRNE homeland security products and comprehensive solutions for a wide range of clients, including government agencies, border control, airports, seaports, HazMat teams, ambulance crews, police, and armed forces. This offering features specialized gamma spectroscopy software for in-depth sample analysis. Furthermore, the company supports scientific research and development through its CZT imaging development platforms, such as the DMatrix and the EV3500 scalable x-ray CZT linear array, designed for laboratory and research applications. Kromek distributes its products through a combination of distributors, original equipment manufacturers (OEMs), and direct sales channels.
Technical Analysis
Gooch & Housego
―
Judges Scientific
―
TT Electronics
―
Windar Photonics
―
discoverIE Group plc
―
Options Prices
Currently, No data available
---








